Arthritis Research & Therapy最新文献

{"title":"The diagnostic utility of lung ultrasound in the assessment of interstitial lung disease associated with rheumatoid arthritis","authors":"Shaoyu Zheng, Zexuan Zhou, Guangzhou Du, Qingzi Chen, Shaoqi Chen, Jianqun Lin, Shijian Hu, Weijin Zhang, Kedi Zheng, Jinghua Zhuang, Meigan Huang, Barbara Ruaro, Cosimo Bruni, Anna-Maria Hoffmann-Vold, Marco Matucci-Cerinic, Daniel E. Furst, Yukai Wang","doi":"10.1186/s13075-025-03626-4","DOIUrl":"https://doi.org/10.1186/s13075-025-03626-4","url":null,"abstract":"To investigate the diagnostic accuracy of lung ultrasound (LUS) for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). This retrospective study included patients over 18 years with RA evaluated at the Department of Rheumatology and Immunology of Shantou Central Hospital. All patients underwent chest high-resolution computed tomography (HRCT) and LUS within one month. The LUS was performed in a total of 50 scanning sites (ScS), and the number of B-lines present in each ScS was counted and summed up as B-lines score. A positive judgement was given on LUS when the B-lines score exceeded 10. The presence and patterns of ILD were defined by HRCT findings. ROC curve analysis was used to calculate the accuracy of LUS to detect ILD. A total of 120 RA patients (86 women, with a median age of 56.0 [50.0–64.0] years) were enrolled. Based on the HRCT, 76 patients were found to have radiographic ILD, with 63 exhibiting nonspecific interstitial pneumonia (NSIP) and 13 showing usual interstitial pneumonia (UIP). Sonographic ILD was detected in 76 patients who underwent LUS examination. The concordance rate between two modalities was 83.33% (Kappa value = 0.64, 95% CI 0.50–0.78). The diagnostic sensitivity and specificity of LUS were 86.84% and 77.27%, respectively. The positive predictive value, negative predictive value, a positive likelihood ratio and a negative likelihood ratio were 86.84%, 77.27%, 3.82, and 0.17, respectively. The number of B-lines in RA with ILD and without ILD on HRCT showed a significant difference (34.0 [15.0–96.5] vs. 6.5 [2.5–10.0], P < 0.001). The presence of 12 B-lines on 50 ScS was the optimal cutoff value for detecting RA-ILD (AUC = 0.89, 95% CI 0.82–0.94, sensitivity of 85.53%, specificity of 81.82%, P < 0.001). Lung ultrasound is a valuable diagnostic tool for RA-ILD and can be used as a screening method to identify patients who require further evaluation with chest HRCT.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144737510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, characteristics, and outcomes of patients with low baseline C-reactive protein in giant cell arteritis","authors":"Samuel Pichon, Vincent Koether, Amélie Leurs, Aurelien Chepy, Benoît Gachet, Vincent Sobanski, David Launay, Marc Lambert, Eric Hachulla","doi":"10.1186/s13075-025-03594-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03594-9","url":null,"abstract":"Elevated inflammatory markers play a crucial role in the diagnosis and follow-up of patients with giant cell arteritis (GCA). This study aimed to describe the prevalence, characteristics, and outcomes of patients with low baseline (< 10 mg/L) C-reactive protein (CRP) in GCA. A retrospective observational study was conducted at Lille University Hospital, involving all patients diagnosed with GCA between January 2000 and April 2023. Patients were categorized based on their CRP level at diagnosis. Baseline characteristics, clinical manifestations, laboratory findings, imaging results, and outcomes were compared between patients with baseline CRP < 10 mg/L (“low CRP”) and those with CRP ≥ 10 mg/L (“high CRP”). Of the 380 patients, 7.6% (n = 29) had baseline CRP < 10 mg/L at diagnosis. When compared to the high CRP group, the low CRP group exhibited a lower incidence of fever, and had a higher incidence of ocular involvement, particularly anterior ischemic optic neuropathy (28% vs. 13%, p = 0.04), and limb claudication (24% vs. 8%, p < 0.01). Plasma fibrinogen levels were elevated (> 4 g/L) in 77% of patients with low CRP. Despite differences in clinical presentation, relapse rates were equilibrated between the two groups. GCA patients with low CRP are not rare and present with more ocular and peripheral vascular involvement and less constitutional symptoms in our study. Elevated fibrinogen in these patients suggests active inflammation despite low CRP. Clinicians should consider GCA even with a CRP < 10 mg/L, as these patients may present with severe complications.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"25 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144737749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of bioactive variants of the BMP7-derived p[63–82] peptide for ameliorating the OA-associated chondrocyte phenotype","authors":"Jessica S. J. Steijns, Tim J. M. Welting, Andy Cremers, Guus G. H. van den Akker, Pieter J. Emans, Lodewijk W. van Rhijn, Marjolein M. J. Caron","doi":"10.1186/s13075-025-03599-4","DOIUrl":"https://doi.org/10.1186/s13075-025-03599-4","url":null,"abstract":"Osteoarthritis is a highly prevalent, age-associated joint disease characterized by cartilage degeneration, joint dysfunction, and chronic pain. We previously developed a bone morphogenetic protein 7 derived peptide p[63–82], which may be a novel disease-modifying treatment option for OA. In this study we aimed to optimize the bioactivity and biostability of this peptide in the intra-articular environment to evaluate the therapeutic potential of these peptides to treat osteoarthritis. 33 peptide modifications of p[63–82] were custom-designed and synthesized to optimize the bioactivity. Chondrocytes and synovial fluid were collected from end-stage osteoarthritic patients at total knee arthroplasty surgery. To validate improvements in bioactivity, gene expression analysis, glycosaminoglycan content, matrix metalloproteinase-13 protein levels and alkaline phosphatase activity was measured. Several biochemical approaches were used to explore optimization of the original p[63–82] peptide. One cyclized peptide (C2) was able to significantly increase the expression of collagen type 2 and decrease expression of collagen type 10, matrix metalloproteinase-13 and prostaglandin-endoperoxide synthase 2. The linear p[63–82] peptide and the cyclic peptide variant C2 in the same concentration were effective in suppressing the osteoartritic phenotype in SW1353 cells, despite the presence of interleukin-1β or osteoarthritic-synovial fluid. However, peptide variant C2 had a significantly more favorable bioactivity as compared to p[63–82] in reducing matrix metalloproteinase-13 protein levels in the osteoarthritic-synovial fluid exposed condition. At lower concentrations, the cyclic peptide C2 showed a higher bioactivity as compared to the linear p[63–82] peptide. When the activity of both peptides on primary human articular chondrocytes was evaluated, we found that the linear p[63–82] peptide as well as peptide C2 counteract the hypertrophic and inflammatory state of primary OA chondrocytes. This study demonstrates that among various tested modifications of p[63–82], one cyclic variant (C2) showed similar results in bioactivity as compared to the linear peptide p[63–82], whilst the other modified peptide variants had inactive bioactive properties as compared to the original p[63–82] peptide. This highlights the challenge in enhancing peptide properties without compromising their biological activity and emphasises the need for a cautious approach in peptide modification for therapeutic use. This research underscores that while cyclization and other structural changes may offer benefits, they should be carefully evaluated on a case-by-case basis.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"10 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144737729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokines, chemokines and antibodies against histone-3/4 citrullinated peptides in rheumatoid arthritis patients with pulmonary fibrosis","authors":"Linda Johansson, Federico Pratesi, Fosca Errante, Lorenzo Pacini, Paola Migliorini, Solbritt Rantapää-Dahlqvist","doi":"10.1186/s13075-025-03603-x","DOIUrl":"https://doi.org/10.1186/s13075-025-03603-x","url":null,"abstract":"Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) is the most common pulmonary manifestations of RA, with a progressive course and a poor survival. An early detection and better treatment is essential to improve outcome. We evaluated 16 analytes that could be relevant for the development of RA ILD. In an inception cohort of 1118 early RA patients, pulmonary fibrosis (PF) were identified in 60 patients after a mean follow-up of 5.3 years using high resolution computer tomography (HRCT). As controls, 124 early RA patients without PF and 94 matched population controls without known rheumatic disease were studied. Analysis of antibodies against histones 3 and 4 derived citrullinated peptides (CitH3/H4), and cytokines/chemokines levels were performed in plasma samples collected at RA diagnosis using in-house ELISA and Luminex analysis. Anti-CitH3(114–135) antibodies were the only antibody with increased frequency and levels in patients with PF versus without PF. The highest OR for PF development were found when combining positivity for anti-CitH3(114–135) and -CitH4(31–50) antibodies, OR 2.26. Levels of IL1α, IL1ß, TNFα, VEGFA and MIPα remained significantly elevated in patients with PF compared without PF, after adjustments and Bonferroni corrections. Several of the cytokines/chemokines correlated significantly with the histone antibodies in patients without PF. Partial least squares discriminant analysis including antibodies against citrullinated histon peptides and cytokines/chemokines identified significantly in PF in non-smokers. Antibodies against CitH3 peptides and several of the analysed cytokines/chemokines in samples collected at diagnosis were associated with subsequent delevopment of PF in patients with RA.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"1 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144737750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases","authors":"Edgar Wiebe, Elisa Celine Schilling, Dörte Huscher, Andriko Palmowski, Zhivana Boyadzhieva, Sandra Hermann, Burkhard Muche, Mirella Lopez Picazo, Gerhard Krönke, Falk Hiepe, Tobias Alexander, Frank Buttgereit","doi":"10.1186/s13075-025-03610-y","DOIUrl":"https://doi.org/10.1186/s13075-025-03610-y","url":null,"abstract":"Patients with systemic lupus erythematosus (SLE) are at higher risk for osteoporosis and fragility fractures. Our study aimed to identify disease-specific factors with impact on bone mineral density (BMD) and the risk of osteoporosis, and to evaluate the effectiveness of DXA-derived 3D femur parameters versus BMD and trabecular bone score (TBS) in discriminating pre-existent fragility fractures. We analyzed baseline data of a consecutive subcohort of patients with SLE with current or past GC treatment, fulfilling the EULAR/ACR 2019 SLE classification criteria. We used multivariable linear and logistic regression models to identify BMD- and osteoporosis-related factors. DXA-derived 3D measurements of the femur were performed with 3D-Shaper software. Discriminatory performance of BMD, TBS and 3D femoral parameters for fragility fractures was assessed by AUC values. Forty-one percent of 110 patients with SLE had osteoporosis. Lupus nephritis (LN) was present in 35% of cases, with 61% (23/38) of these being predominantly classified as classes IV and V. Factors significantly associated with lower BMD included LN classes III and IV, U1-RNP antibodies, higher C-reactive protein, and longer disease duration. Clinical remission, higher Siglec-1 levels, higher body mass index, and higher health assessment questionnaire (HAQ) scores correlated positively with BMD. Osteoporosis was linked to LN, higher age, HAQ, and complement factor 3 levels. Our findings suggest that 3D bone structure analysis may be helpful in discriminating past vertebral fractures. Disease severity indicated by LN, high CRP, presence of U1-RNP antibodies, and extended disease duration are detrimental to bone health. Moreover, 3D-DXA parameters can be integrated in clinical practise to assess bone health. ","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"10 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)","authors":"Vasiliki Liakouli, Giulio Forte, Piero Ruscitti, Luca Navarini, Francesca Bellisai, Francesco Caso, Giuliana Guggino, Lidia La Barbera, Chiara Rizzo, Ada Corrado, Paola Triggianese, Alberto Lo Gullo, Giuseppe Mandraffino, Luca Cantarini, Bruno Frediani, Paola Cipriani, Francesco Paolo Cantatore, Maria Sole Chimenti, Elvira Favoino, Federico Perosa, Annamaria Iagnocco, Roberto Giacomelli, Francesco Ciccia","doi":"10.1186/s13075-025-03619-3","DOIUrl":"https://doi.org/10.1186/s13075-025-03619-3","url":null,"abstract":"To assess the contribution of Systemic sclerosis (SSc)-specific features on type II diabetes mellitus (T2D) in a large cohort of Italian SSc patients. A total of 613 SSc patients from 11 tertiary Rheumatology Units across Italy were included. All patients underwent full history taking, clinical examination, and relevant laboratory and radiological evaluations. Demographic, socioeconomic, and disease-specific factors were compared between SSc patients with and without T2D. The prevalence of T2D in the study cohort was 7.6%. SSc patients with T2D were significantly older (P < 0.007) and exhibited: higher prevalence of late-stage capillaroscopic pattern (P < 0.001), severe reduction in forced vital capacity (FVC < 50%; P < 0.000), moderate reduction in total lung capacity (TLC 50–69%; P < 0.011), electrocardiographic signs of right ventricular hypertrophy (P < 0.018), higher prevalence of pulmonary arterial hypertension (PAH) confirmed by right heart catheterization (RHC) (P < 0.037) and higher prevalence scleroderma renal crisis (SRC) (P < 0.001); elevated erythrocyte sedimentation rate (ESR) (P < 0.022), and ANA positivity. These patients more frequently assumed angiotensin-converting enzyme inhibitors (ACEi) (P < 0.005) when compared to their non-T2D counterparts, while the use of immunosuppressive therapies was similar between groups. Multivariate analysis identified older age, SRC, and reductions in both TLC and FVC as independent SSc-specific associated factors of T2D. Although the prevalence of T2D in SSc patients is lower than the global estimates reported by the International Federation of Diabetes (IFD), a distinct subgroup of SSc patients with T2D is characterized by unique disease manifestations and complications, including SRC and impaired lung function. These findings underscore the importance of tailored screening and management approaches to address the intersecting metabolic and vascular risks in this population.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"56 12 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort","authors":"Tahzeeb Fatima, Yuan Zhang, Georgios K. Vasileiadis, Araz Rawshani, Ronald van Vollenhoven, Jon Lampa, Bjorn Gudbjornsson, Espen A. Haavardsholm, Dan Nordström, Gerdur Gröndal, Kim Hørslev-Petersen, Kristina Lend, Marte S. Heiberg, Merete Lund Hetland, Michael Nurmohamed, Mikkel Østergaard, Till Uhlig, Tuulikki Sokka-Isler, Anna Rudin, Cristina Maglio","doi":"10.1186/s13075-025-03616-6","DOIUrl":"https://doi.org/10.1186/s13075-025-03616-6","url":null,"abstract":"The variability in treatment response in people with rheumatoid arthritis (RA) warrants the prediction of patients at high risk of treatment failure. Identification of biomarkers linked to clinical remission in RA is currently a challenge. Metabolomics may help to identify such biomarkers as it allows for a comprehensive exploration of disease-related variations that extends beyond the genome and proteome. This hypothesis-free exploratory metabolomics study aimed to profile serum metabolic alterations in early RA to understand the metabolic changes associated with disease activity and therapeutic response. The study included 220 early RA participants from the NORD-STAR study, randomized at baseline into four arms, ranging from conventional anti-rheumatic treatment to biological drugs: methotrexate combined with prednisolone (1), certolizumab (2), abatacept (3), or tocilizumab (4). Untargeted metabolomics was performed in serum samples at baseline and 24-week follow-up. Participants achieving clinical disease activity index remission at 24 weeks were defined as responders. Machine learning models for treatment response were constructed using random forest, logistic regression, support vector machine and extreme gradient boosting algorithms based on selected features. We identified 278 metabolites, of which 39 were associated with baseline disease activity, including several acylcarnitines and amino acids. We also found 17 baseline metabolites associated with remission at 24 weeks in the overall cohort, including malic acid (β=-0.4), cytidine (β = 0.4), arginine (β = 0.3), and citrulline (β = 0.2), as well as specific metabolites and metabolic pathways associated with remission in the four treatment arms. Fifteen features were identified using machine learning-based multivariable selection. The best predictive model using logistic regression achieved AUC of 0.75 in training and 0.73 in the test set. Our study has identified several baseline metabolites and metabolic pathways associated with disease activity and response to different treatments in early RA. By integrating metabolomics and clinical data, we developed predictive models for response to treatment in early RA, though their predictive performance remains limited.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"2 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort","authors":"Rangi Kandane-Rathnayake, Worawit Louthrenoo, CS Lau, Laniyati Hamijoyo, Jiacai Cho, Aisha Lateef, Shue Fen Luo, Yeong-Jian Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Yi-Hsing Chen, Shereen Oon, Madelynn Chan, Sargunan Sockalingam, Yanjie Hao, Zhuoli Zhang, Sang-Cheol Bae, Jun Kikuchi, Tsutomu Takeuchi, Yasuhiro Katsumata, BMDB Basnayake, Fiona Goldblatt, Sean O’Neill, Kristine Pek Ling Ng, Nicola Tugnet, Mark Sapsford, Yih Jia Poh, Cherica Tee, Michael Tee, Naoaki Ohkubo, Adrienne O’Donnell Lefeber, Tamas Shisha, Yoshiya Tanaka, Vera Golder, Mandana Nikpour, Alberta Hoi, Peter Gergely, Eric Morand","doi":"10.1186/s13075-025-03622-8","DOIUrl":"https://doi.org/10.1186/s13075-025-03622-8","url":null,"abstract":"Emerging therapies have the potential to be used in patients with severe refractory systemic lupus erythematosus (srSLE), but no agreed definition of srSLE exists. We evaluated a pilot srSLE definition to assess whether a set of disease activity and treatment thresholds could identify patients with poor outcomes. Data from a 13-country longitudinal SLE cohort, collected prospectively between 2013 and 2020 were analysed. srSLE was defined if a patient was in high disease activity (SLEDAI-2K ≥ 10) despite combination use of at least glucocorticoids (GC) and immunosuppressants (IS) at both the index and preceding visit. Synchronised to the index srSLE visit, we assessed disease activity, medication use and treat-to-target (T2T) endpoint attainment over 12 months (m). Of 3,744 patients studied, 578 (14%) had srSLE, in 1,810 visits. The median [IQR] SLEDAI-2K at the srSLE index visit was 12 [10, 14], which decreased to 6 [4, 10] at 6m and 12m. Most patients remained on combination anti-malarial, GC, and IS at all follow-up time points. The median [IQR] GC dose at the index visit was 10 [5, 20] mg/day; this reduced to 8 mg [5.0, 12.9] at 6m and 5 mg [5.0, 10.0] at 12m. Less than a quarter of patients attained LLDAS and only 1% attained GC-free remission over 12 months. A draft definition of srSLE was clearly associated with poor outcomes. Work to evaluate multiple thresholds with which to define srSLE, and their outcomes, is warranted.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"667 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality in polymyalgia rheumatica: a 38-year prospective population-based cohort study from Southern Norway","authors":"Stig Tengesdal, Øyvind Molberg, Øyvind Holme, Jan Tore Gran, Geirmund Myklebust","doi":"10.1186/s13075-025-03613-9","DOIUrl":"https://doi.org/10.1186/s13075-025-03613-9","url":null,"abstract":"Robust long-term mortality data on patients with polymyalgia rheumatica (PMR) are lacking. The aim of this study was to determine all-cause mortality in isolated PMR using a large, population-based, inception cohort followed prospectively over a 38-year period. Between 1987 and 1997, 337 incident cases of PMR and biopsy-proven GCA were included in a prospective, population-based inception cohort in Aust-Agder County, Norway. Diagnosis was ascertained clinically by a rheumatologist, with PMR cases meeting Bird`s criteria. Patients were followed until death or end of study on December 31st, 2024. Each case was matched by gender, age at inclusion, and residency with 15 population comparators drawn from the population registry in Norway. We assessed mortality and survival by standard mortality ratios (SMR) and the Kaplan-Meier method. A total of 274 patients with isolated PMR (66.1% female, mean age at diagnosis 71.9 years) and 63 patients with GCA (76.2% female, mean age at diagnosis 71.6 years) were included. By the end of the study, 96.4% of all patients were deceased. Mean follow-up time for all patients was 13.7 years, with a maximum of 35.3 years. For cases with isolated PMR, the overall SMR was 0.97 (95% confidence interval [CI] 0.85, 1.09), for men 0.77 (95% CI 0.62, 0.95), and for women 1.11 (95% CI 0.95, 1.28). For GCA, the overall SMR was 1.10 (95% CI 0.85, 1.40), with no gender difference. In this comprehensive long-term follow-up study with nearly complete data on mortality, isolated PMR was not associated with increased mortality, reinforcing the view that it does not confer a higher mortality risk.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"5 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis identifies the major impact of patient classification on the ACPA association with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","authors":"Bartosz Kaczmarczyk, Carmen Conde, Antonio Gonzalez","doi":"10.1186/s13075-025-03617-5","DOIUrl":"https://doi.org/10.1186/s13075-025-03617-5","url":null,"abstract":"We need screening for RA patients at high risk of RA-ILD to prevent the associated decrease in life quality and survival. The proposed screenings disagree regarding the anti-citrullinated protein antibodies (ACPA) because of their inconsistent association across recent studies. Therefore, we hypothesized that meta-analysis of the published reports should reveal clues explaining the heterogeneity of results, helping us progress in RA-ILD early detection. We aimed to discover the factors accounting for the variability of the ACPA association in the published reports. We searched the Web of Science and PubMed databases for studies reporting ACPA in RA-ILD and RA-control groups. The identified studies were analyzed using meta-analysis and meta-regression to identify moderators of the ACPA association. We found 513 unique records, containing 31 eligible data sets. The meta-analysis preceding the search for moderators showed a remarkable heterogeneity (pQ = 5.7 × 10–7). Appropriate tests showed that it was largely attributable (58.1%) to an outlier study, which had recruited cases and controls in different place and time contexts. The exclusion of this outlier from subsequent analyses did not completely remove heterogeneity (pQ = 0.004). However, it permitted the identification of the patient classification method as a significant moderator: The 14 studies using chest CT showed stronger ACPA association with RA-ILD (OR = 3.05 [95%CI: 2.12–4.38]) than the 16 employing multifactorial criteria (1.55 [95%CI: 1.18–2.03]; p = 0.0047 for the contrast). This moderator accounted for the significant heterogeneity (pQ = 0.079), was robust in sensitivity analyses, and was the only one found. Our results validate the ACPA association with RA-ILD, reinforce the importance of study design, and suggest the need to consider if studies relying on chest CT for classification could be more fruitful in the search for RA-ILD biomarkers.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"24 1","pages":"151"},"PeriodicalIF":4.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}